Carcinoma of Unknown Primary in a Patient With Lynch Syndrome

Nat C. Jones, Jacob J. Adashek, Bassam Ayoub

1. Internal Medicine, University of South Florida (USF) Health, Tampa, USA

Corresponding author: Jacob J. Adashek, jadashek@westernu.edu

Abstract
Lynch syndrome is the most common form of hereditary colorectal cancer and is associated with an increased incidence of endometrial cancer, small bowel cancer, and other malignancies. The advent of immune checkpoint blockade, next-generation sequencing, and precision medicine molecular tumor boards have revolutionized the current treatment landscape for many cancers and allowed for more creative approaches to treating patients. In addition, tissue agnostic approvals have also served as valid treatment options for patients with otherwise untreatable cancers. In this report, we discuss the case of a 70-year-old woman with Lynch syndrome found to have retroperitoneal lymphadenopathy with p16-negative squamous cell carcinoma, diagnosed as carcinoma of unknown primary (CUP). To our knowledge, this is the first report of Lynch syndrome–associated squamous cell CUP. More research is needed on newly emerging cancer presentations in Lynch syndrome patients as they achieve longer lifespans.

Keywords: cancer immunotherapy, translational and precision medicine, carcinoma of unknown primary, next-generation sequencing, tissue agnostic approval

Introduction
Lynch syndrome is the most common form of hereditary colorectal cancer, accounting for 2–5% of all colorectal cancers [1]. It is also associated with increased incidences of endometrial cancer, small bowel cancer, and several other malignancies [2]. It is characterized by mutations in mismatch repair (MMR) genes, such as MLH1, MSH2, MSH6, and PMS2, which were observed in 13.8% of patients in a colorectal cancer cohort study [3].

There is a paucity of reports describing squamous cell carcinomas (SCC) in patients with Lynch syndrome, with many such reports being on cutaneous SCC [4]. The few instances of Lynch syndrome–associated non-cutaneous SCC that have been reported are thought to be attributed to progressively increasing lifespans of patients with Lynch syndrome who live longer lives with better management of their classically-described cancers, and novel pathologies are now emerging [5].

Carcinoma of unknown primary (CUP) is by default a diagnosis of exclusion. This diagnosis is coined when the histopathology is unclear and a primary tumor cannot be identified. CUPs can have characteristics of adenocarcinomas, undifferentiated carcinomas, and SCCs [6]. Because CUP is a rare diagnosis and treatment generally includes combination chemotherapy without immunotherapy or targeted therapies, patient prognoses are generally poor [7]. The median overall survival (OS) for patients diagnosed with CUP is ~5 months, with improved survival in recent years for some subsets of patients with CUP [8].

In this report, we discuss the case of a patient with Lynch syndrome and a remote history of endometrial and rectal adenocarcinomas and newly diagnosed CUP of squamous origin. To our knowledge, this represents the first reported case of squamous CUP in a patient with Lynch syndrome.

Case Presentation
A 70-year-old woman with a history of Lynch syndrome with Muir-Torre variant [9], who previously had undergone a total abdominal hysterectomy, bilateral salpingo-oophorectomy, and para-aortic lymph node resection with adjuvant radiation in 1997 for stage IIIC endometrial adenocarcinoma and more recently underwent an abdominal perineal resection for stage IIA TNM0M0 rectal adenocarcinoma where immunohistochemistry (IHC) of her rectal mass showed loss of PMS2 and MLH1, with normal MSH2/6, presented with three months of nausea, vomiting, weakness, and 20-pound weight loss.

She underwent a computed-tomography scan, which revealed a new right-sided 7.3 cm retroperitoneal (RP) mass with additional lymphadenopathy, and underwent a biopsy of the retroperitoneal mass. The pathology revealed squamous histology, negative for p16, inconsistent with her prior adenocarcinomas, making disease recurrence less likely and suggesting a new primary SCC. Endoscopic evaluations of her oropharynx and larynx and both gynecologic/rectal exams failed to identify a primary site of the SCC. A positron emission...
tomography revealed hypermetabolic left supraclavicular, para-aortic, and mesenteric lymph nodes in addition to the 7.3-cm centrally necrotic RP mass (Figures 1, 2). Thus, the diagnosis of CUP was confirmed. The RP biopsy was sent for next-generation sequencing (NGS), which revealed microsatellite instability-high (MSI-H) and a tumor mutational burden (TMB) of 15 mutations/megabase (mt/mB). Genomic analysis, including a 324 gene panel, revealed mutations in ATM, ARID1A, and KRAS.

**FIGURE 1: Positron emission tomography scan of the retroperitoneal mass**

Axial view of the 7.3-cm centrally necrotic retroperitoneal mass is visualized along with a hypermetabolic left para-aortic lymph node.
The patient was planned to receive pembrolizumab based on having both MSI-H and TMB of 15 mt/mB. Two days prior to the planned time of treatment initiation, the patient acutely decompensated and expired in the intensive care unit.

**Discussion**

Precision medicine offers exciting possibilities for the treatment of cancer. Although this patient expired due to an acute complication, her NGS results indicated several reasons for a potential response to immune checkpoint inhibition (ICI). Pembrolizumab is tissue-agnostically approved for tumors with MSI-H \[10\] and $\geq 10$ mt/mB TMB \[11\], and our patient met the criteria for both of these independent FDA approvals. Our patient’s tumor ARID1A mutation also supports a potential response to ICI \[12\]. Further, Lynch syndrome patients have been shown to have durable responses to ICI in various tumors, likely due to their germline MMR mutations \[13\].

There are potential reasons why our patient may not have responded to pembrolizumab. Even though the FDA approval is for $\geq 10$ mt/mB TMB, patients with "high" TMB ($>20$ mt/mB) have been observed to respond better to ICI \[14\]. Although it is unclear why high TMB confers response to ICI, this is generally an accepted fact within the oncology community with a multitude of mechanistic hypotheses. Our patient classically would be referred to as "intermediate" TMB status (6–19 mt/mB), which has implications for lower ICI efficacy \[15\]. Additionally, her KRAS and ATM mutations would not have been targeted with pembrolizumab alone, but a logical combination of pembrolizumab with a KRAS inhibitor such as sotorasib and poly (ADP-ribose) polymerase (PARP) inhibitor like olaparib might have more comprehensively treated her cancer.

**FIGURE 2: Positron emission tomography scan of the retroperitoneal mass**

Coronal view of the 7.3-cm centrally necrotic retroperitoneal mass is visualized along with hypermetabolic left supraclavicular, para-aortic, and mesenteric lymph nodes.
A combination regimen would have likely been ideal, as patients with CUP have been shown to have meaningful responses to drugs that target specific mutations observed on NGS [18, 19]. Patients with CUP who are given drugs that target >50% of their mutations found on NGS have longer progression-free survival (95% confidence interval (CI), 0.11-0.64; hazard ratio (HR), 0.27; P=0.002), disease control rate (71% vs. 24%; P=0.003), and overall survival (95% CI, 0.17-1.16; HR, 0.45; P=0.09) [20].

Conclusions

Although Lynch syndrome is the most common form of hereditary colorectal cancer and is associated with an increased incidence of endometrial cancer, there is much to be learned about the unique cancer manifestations that may arise in these patients. To our knowledge, this is the first report of Lynch syndrome–associated squamous cell CUP initially found in a retroperitoneal lymph node. Additional research is needed on emerging cancer presentations in Lynch syndrome patients, as these patients continue to live longer with precision medicine serving as a new frontier for the treatment of such novel cancers.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl J Med. 2005, 348:919-52. 10.1056/NEJMra012242
2. Lindor NM, Greene MH; Mayo Familial Cancer Program: The concise handbook of family cancer syndromes. J Natl Cancer Inst. 1998, 90:1059-71. 10.1093/jnci/90.14.1059
3. Moreira L, Balaguer F, Lindor N, et al.: Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 2012, 308:1555-65. 10.1001/jama.2012.13088
4. Adan F, Grijns MB, Dekker E, et al.: A squamous cell carcinoma in a young woman with Lynch syndrome. Fam Cancer. 2019, 18:195-6. 10.1007/s10689-018-00115-5
5. Amjad AI, Singhdi AD, Balahan EP, Dudley B, Brand RE, Bahary N: First reported case of a squamous cell carcinoma arising in the duodenum in a patient with Lynch syndrome. Int J Clin Exp Pathol. 2014, 7:8988-95.
6. Collado Martín R, García Palomo A, de la Cruz Merino L, Borrega García P, Barón Duarte FJ: Clinical guideline SEOM: cancer of unknown primary site. Clin Transl Oncol. 2014, 16:1091-7. 10.1007/s10661-014-1244-9
7. Altman E, Cadman E: An analysis of 1539 patients with cancer of unknown primary site . Cancer. 1986, 57:120-4. 10.1002/1097-0142(19860101)57:1<120::AID-CNCN2820570124>3.0.CO;2-m
8. Riihimäki M, Hemminki A, Sunquist K, Hemminki K: Time trends in survival from cancer of unknown primary: small steps forward. Eur J Cancer. 2015, 49:2403-10. 10.1016/j.ejca.2015.02.022
9. Punti G, Ponz de Leon M: Muir-Torre syndrome. Lancet Oncol. 2005, 6:980-7. 10.1016/S1470-2045(05)70465-4
10. Marcus L, Lemery SJ, Keegan P, Pazdur R: FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019, 25:3753-8. 10.1158/1078-0432.CCR-18-4070
11. Adashek JJ, Subbiah V, Kurzrock R: From tissue-agnostic to N-of-one therapies: (r)evolution of the precision paradigm. Trends Cancer. 2021, 7:15-28. 10.1016/j.trecan.2020.08.009
12. Okamura R, Kato S, Lee S, Jimenez RE, Sicklick JK, Kurzrock R: ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. J Immunother Cancer. 2020, 8:e004538. 10.1186/s12094-019-00458
13. Bari S, Kim RD, Wang X, Matejic M, Zuffarri J: Outcomes of Lynch syndrome (LS) patients treated with immune checkpoint inhibitors (ICI). J Clin Oncol. 2020, 38:1548. 10.1200/JCO.2020.38.15_suppl.1548
14. Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R: Microsatellite-stable tumors with high mutational burden benefit from immunotherapy. Cancer Immunol Res. 2019, 7:1570-3. 10.1158/2326-6066.CIR-19-0149
15. Goodman AM, Kato S, Razenhova L, et al.: Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017, 16:2598-608. 10.1158/1535-7163.MCT-17-0386
16. Hong DS, Fakih MG, Strickler JH, et al.: KRAS G12C inhibition with sotorasib in advanced solid tumors . N Engl J Med. 2020, 383:1207-17. 10.1056/NEJMoa1917239
17. Gatz S, Pethkofer L, Morawe M, et al.: Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut. 2021, 70:745-60. 10.1136/gutjnl-2019-319970
18. Kato S, Krishnamurthy N, Banks KC, et al.: Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary. Cancer Res. 2017, 77:4238-46. 10.1158/0008-5472.CAN-17-0628
19. Adashek JJ, Kato S, Parulkar R, et al.: Transcriptomic silencing as a potential mechanism of treatment.
resistance. JCI Insight. 2020, 5:e134824. 10.1172/jci.insight.134824

20. Adashek J, Kato S, Gumas S, Lee S, Okamura R, Sicklick J, Kurzrock R: 86MO Personalized molecularly matched therapies for carcinomas of unknown primary is associated with improved outcomes. Ann Oncol. 2020, 31:S275-6. 10.1016/j.annonc.2020.08.207